Jeremy S Frieling

6PUBLICATIONS
37CO-AUTHORS
Predictive and prognostic markersCancer cell biologyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Oct 17, 2025
PRDM16 Regulates Prostate Cancer Cell Dormancy and Prevents Bone Metastatic Outgrowth.

Mostafa M Nasr, Bishoy Wadie, Tao Li

|Apr 29, 2025
Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and Suppresses Bone-Metastatic Prostate Cancer.

Catherine S Johnson, Diane Costanzo-Garvey, Julio C Valencia

|Dec 02, 2024
Tales of Cancer-Induced Bone Disease from the Senescent Osteocyte Crypt.

Jeremy S Frieling, Conor C Lynch

|Mar 20, 2024
The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease.

Ryan T Bishop, Anna K Miller, Matthew Froid

|May 03, 2023
γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer.

Jeremy S Frieling, Leticia Tordesillas, Xiomar E Bustos

|Feb 02, 2021
Mesenchymal stem cell-derived interleukin-28 drives the selection of apoptosis resistant bone metastatic prostate cancer.

Jeremy J McGuire, Jeremy S Frieling, Chen Hao Lo

Pageof 1